Search
Tutorial on acute leukemia held in Istanbul
EHA and the Turkish Society of Hematology (TSH) partnered for the seventh time to organize a tutorial.
Read moreHighlights of Past EHA (HOPE) Latin America (LA) 2023 - report
October 26, 2023 – São Paulo, Brazil
Meeting chairs:
A Almeida - President EHA
JF Comenalli Marques Jr - President ABHH
C Chiattone - President HEMO 2023
This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…
A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.
Read morePublications
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.
SWG Educational Activities
Social and public activitiesSince 2020, Prof Hermann Einsele has been a Councilor to the EHA Board. Scientific activitiesFifth European CAR T-cell meetingDateFebruary 9–11, 2023. LocationRotterdam, The Netherlands.
Read moreTwo genes cooperate to trigger leukemia development
Congratulations to the international group of researchers led by HemaSphere Editor-in-Chief Prof.
Read moreInternational CML adherence survey launched
The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.
Read morePublications
Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…